Inotuzumab ozogamicin with bosutinib for relapsed ... | 動物用藥查詢網
![Inotuzumab ozogamicin with bosutinib for relapsed ...](https://i.imgur.com/TbfVXFL.jpg)
由NJain著作·2021·被引用21次—Relapsed/refractory(R/R)Philadelphiachromosomepositiveacutelymphoblasticleukemia(Ph+ALL)andlymphoidblastphaseofchronic ...
![Inotuzumab ozogamicin with bosutinib for relapsed ...](https://i.imgur.com/TbfVXFL.jpg)
Relapsed/refractory (R/R) Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) and lymphoid blast phase of chronic myeloid leukemia (LBP-CML) have poor outcomes. We designed a phase 1/2 study combining inotuzumab ozogamicin with bosutinib for this patient population. Patients with T315I mutation were excluded. Bosutinib was administered daily at three dose levels (300 mg/d, 400 mg/d, 500 mg/d) in a 3 + 3 design. Inotuzumab ozogamicin was dosed weekly during cycle one, and once every 4 weeks subsequently for a total of six cycles. The primary objective was to determine the safety and the maximum tolerated dose (MTD) of bosutinib in combination with inotuzumab ozogamicin. Eighteen patients were enrolled (Ph-positive ALL, n = 16; LBP-CML, n = 2). The median age was 62 years (range, 19-74) and the median number of prior therapies was one (range, 1-5). Dose limiting toxicities included grade 3 skin ra...
ALL新藥inotuzumab ozogamicin獲健保給付 | 動物用藥查詢網
Inotuzumab ozogamicin | 動物用藥查詢網
Inotuzumab ozogamicin as single agent in pediatric patients ... | 動物用藥查詢網
Inotuzumab Ozogamicin for RelapsedRefractory ... | 動物用藥查詢網
Inotuzumab ozogamicin in the treatment of acute ... | 動物用藥查詢網
Inotuzumab ozogamicin with bosutinib for relapsed ... | 動物用藥查詢網
Inotuzumab Ozogamicin-成人急性淋巴性白血病治療新 ... | 動物用藥查詢網
Phase II Trial of Inotuzumab Ozogamicin in Children ... | 動物用藥查詢網
認識化療藥品Inotuzumab | 動物用藥查詢網
![](https://i.imgur.com/TbfVXFL.jpg)
百利先12%注射劑 POLYCIDE 12% INJ
百利先12%注射劑有哪些副作用?由公源藥品股份有限公司觀音廠製造的百利先12%注射劑是治療什麼的?藥品成分是什麼?以下為大...
![](https://i.imgur.com/TbfVXFL.jpg)
百利先24%注射劑 POLYCIDE 24% INJ.
百利先24%注射劑有哪些副作用?由公源藥品股份有限公司觀音廠製造的百利先24%注射劑是治療什麼的?藥品成分是什麼?以下為大...